Listen
DELPRIM (trimethoprim), antibiotic
INFECTIOUS DISEASE - New medicinal product
Opinions on drugs -
Posted on
Oct 13 2016
Reason for request
Inclusion
No clinical benefit demonstrated in the treatment of acute uncomplicated cystitis in women and adolescents.
- DELPRIM has Marketing Authorisation in the treatment of acute uncomplicated cystitis in women and adolescents, at the dosage of 300 mg/day for 3 days.
- The efficacy of trimethoprim, although poorly evaluated at this dosage, seems to be similar to that of alternative medicinal products. Data in adolescents are limited.
- DELPRIM is not indicated for use in empirical therapy.
- It is a new treatment option in case of documented infection with ESBL-producing E. coli, as an alternative to trimethoprim-sulfamethoxazole combination therapy and to a fluoroquinolone, prescription of which should be considered in case of more severe infections.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
